TTPH Tetraphase Pharmaceuticals Inc.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Latest News

1. 16 March 2020 Tetraphase Pharmaceuticals and AcelRx Pharmaceuticals Enter into Definitive Merger Agreement

   AcelRx to Acquire Tetraphase in an all-stock transaction Tetraphase equity holders to own 14.6% of the combined company and receive Contingent Value Rights worth up to $12.5 Million Acquisition Expected to Close in

2. 12 March 2020 Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Highlights Achievements and Key 2020 Milestones

   XERAVA Carton Sales Grew over 45% Compared with the Third Quarter of 2019 XERAVA is on formulary or available at 1,200 Institutions Increased Formulary Uptake, with a 99% Success Rate for all Formulary Reviews to

3. 22 January 2020 Tetraphase Pharmaceuticals Announces $17.5 Million of Financings Priced At-the-Market

   Proceeds Will Fund the Commercialization of XERAVA Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to

4. 12 November 2019 Tetraphase Pharmaceuticals Reports Third Quarter 2019 Financial Results and Highlights Recent Corporate Developments

   XERAVA™ Carton Sales Grew over 30% Compared with Second Quarter of 2019 Increased Formulary Uptake, with a 99% Success Rate for all Formulary Reviews to Date -Company to Hold Conference Call Today at 4:30 PM

5. 05 November 2019 Tetraphase Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call

   Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced that company management will

6. 01 November 2019 Tetraphase Pharmaceuticals Announces Completion of $8 Million Registered Direct Offering Priced At-the-Market

     Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection) to treat serious and life-threatening infections,

7. 30 October 2019 Tetraphase Pharmaceuticals Announces $8 Million Registered Direct Offering Priced At-the-Market

   Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today

8. 26 September 2019 Tetraphase Pharmaceuticals Announces Reverse Stock Split

   Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections,

9. 25 September 2019 Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) Data at IDWeek 2019

   – Seven Abstracts Selected for Poster Presentations – Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection)

10. 03 September 2019 Tetraphase Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today